MedTrace Logo

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

NCT04699838 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-02

No results posted yet for this study

Summary

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.

Conditions

Interventions

DRUG

Cisplatin

Cisplatin

DRUG

Carboplatin

Carboplatin

DRUG

Etoposide

Etoposide

DRUG

Durvalumab

Durvalumab

DRUG

Ceralasertib

Ceralasertib

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Muhammad Furqan

    lead OTHER

Principal Investigators

  • Muhammad Furqan, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2026-03-31
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04699838 on ClinicalTrials.gov